OrsoBio announces positive topline Phase 1b/2a clinical data for its oral mitochondrial protonophore TLC-6740 in combination ...
MedPage Today on MSN
One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk
But it's not time to prescribe tirzepatide outside current indications, expert says ...
Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...
The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and ...
The SURMOUNT-1 trial evaluated Tirzepatide a dual GIP/GLP1 agonist, in individuals with overweight (BMI more than or equal to ...
In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...
The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...
Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection has been less clear. A team at Mass General Brigham set out to compare both ...
Congress has the power to make obesity treatment and weight management accessible to the communities that need it.
11hon MSN
Is Eli Lilly a buy before 2026?
Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio.
6hon MSN
The Highly Anticipated “Triple Agonist” Weight Loss Med Is Almost Here—What Doctors Say About It
Phase 3 clinical trial results are out now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results